KOKarima Oualla

Karima Oualla

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Karima Oualla has a total of 59 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    B2B: Bladder Cancer Summary

    by Peter C. Black, Kilian M. Gust, Paramananthan Mariappan, Jeremy Y. C. Teoh, Stephen B. Williams, Karima Oualla, Robert Jones, Daniele Raggi, Viktor Grünwald

    The 7th Bench-to-Bedside Uro-Oncology: GU Cancers Triad Meeting, organized in conjunction with the 45th Annual Congress of the Société Internationale d’Urologie, was held on 31 October 2025, in Edinburgh, Scotland, and transmitted live on the SIU@U Congress app

  • Open Access

    B2B: Kidney Cancer Summary

    by Simon Tanguay, Viktor Grünwald, Arnaud Méjean, Axel Bex, Amy Clifford, Christian Kollmannsberger, Karima Oualla

    The 7th Bench-to-Bedside Uro-Oncology: GU Cancers Triad Meeting, organized in conjunction with the 45th Annual Congress of the Société Internationale d’Urologie, was held on 31 October 2025, in Edinburgh, Scotland, and transmitted live on the SIU@U Congress app

  • Open Access

    B2B: Bladder Cancer Summary

    by Peter C. Black, Seth P. Lerner, Mihir M. Desai, Badrinath R. Konety, Shilpa Gupta, Amit Joshi, Karima Oualla, Senthil Rajappa, Vineet Talwar, Gagan Prakash, et al.

    The 6th Bench-to-Bedside Uro-Oncology: GU Cancers Triad Meeting, organized in conjunction with the 44th Annual Congress of the Société Internationale d’Urologie, was held on 25 October 2024, in New Delhi, India, and transmitted live on the SIU@U Congress platform

  • Immunotherapy in urothelial carcinoma of bladder : therapeutic advances in 2023

    by Lamiae Amaadour, Lamiae Nouiekh, Karima Oualla, Zineb Benbrahim, Samia Arifi, Nawfel Mellas

  • Open Access

    Mediastinal NUT carcinoma: about a case report including immunotherapy in therapeutic management

    by Soukaina El Anssari, Youssef Elhaitmy, Lamiae Amaadour, Karima Oualla, Zineb Benbrahim, Samia Arifi, Mellas Nawfel

    NUT carcinoma (NC), also known as NUT midline carcinoma, is a rare, genetically defined and highly lethal undifferentiated carcinoma occurring in the midline location of the neck, head or mediastinum. We present the case of a 36-year-old Caucasian women who consulted for dyspnea, cough and night sweats. An injected scan showed a large mediastinal mass with lymph node invasion. Transbronchial biopsies confirmed the diagnosis of NUT carcinoma. The ribonucleic acid (RNA) panel molecular biological analysis concluded in the presence of a fusion transcript bromodomain-containing protein 4 (BRD4): NUTM1 (NUT Midline Carcinoma Family Member 1) consistent with the diagnosis of NUT carcinoma. A first line treatment was administered combining immunotherapy and chemotherapy. Through this case report, we will discuss the different therapeutic options and the benefit observed in terms of survival after the addition of immunotherapy.

  • Open Access

    Afebrile chemotherapy-induced neutropenia: an international survey spots oncologists’ routine clinical practice versus the standard of care and the impact of COVID-19

    by Ereny Samwel Poles Saad, Karima Oualla, Narmin Talibova, Snezhanna Gening, Shady Gayed YousefYousef

    Introduction: Afebrile chemotherapy-induced neutropenia represents a frequent clinical situation where chemotherapy protocol, patient’s comorbidities, and disease status determine the risk of infection hence the management plan. Internationally distributed, this questionnaire aims to evaluate the routine practice and the impact of the COVID-19 pandemic on afebrile chemotherapy-induced neutropenia management. Material and methods: Coordinators from Egypt, Morocco, Azerbaijan, and Russia developed a 12-item questionnaire using Google forms to explore how oncologists deal with afebrile chemotherapy-induced neutropenia. The link to the survey was available internationally through social media and to their local societies over the period from July to September 2021. Results: We received 151 responses from 4 world regions: 58.9, 9.9, 11.3, and 15.2% from the Mena area, Russia, Europe, and Asia. The responses deviated from the guideline-driven practice as G-CSF was the most chosen option for intermediate risk that was statistically different based on the academic background of the treating physician. Half of the responders ignored patients and disease risk factors in the intermediate-risk cases that trend was statistically different based on the geographical distribution. The steroid was a valid option for intermediate and low-risk as per oncologists practicing in Russia. COVID-19 pandemic positively affected the rate of prescription of G-CSF as expected. Conclusion: The disparities in the routine practice of oncologists based on their geographical and academic backgrounds highlight the need to analyze the underlying obstacles that hinder guideline-based practice like workload or lack of the proper knowledge.


  • Open Access

    Therapeutic Approaches With Immune Checkpoint Inhibitors in Head and Neck Cancers and the Role of PD-L1 as a Biomarker

    by Karima Oualla, Luis Castelo Branco, Lamiae Nouiyakh, Lamiae Amaadour, Zineb Benbrahim, Samia Arifi, Nawfel Mellas

    Head and neck squamous cell carcinoma (HNSCC) is a potential curative disease at its localized stage, by the use of multimodal treatment including surgery, radiation, and chemotherapy. While the metastatic stage is considered incurable and is characterized by poor prognosis. Conventional cytotoxic chemotherapy in addition to cetuximab were the only available systemic treatment with limited efficacy and modest median overall survival barely crossing the 1 year limit. Immunotherapy with PD-1 and PD-L1 inhibitors has revolutionized the treatment of multiple cancers. Recently, Immunotherapy is being extensively explored in head and neck cancer and clinical trials have shown impressive results that allowed to immune check point inhibitors to be the new standard of care. In this article we tried to explain the rationale and mechanisms of targeting the immune system in head and neck carcinoma and to report the results from the phase III clinical trials that put the immunotherapy as a new standard of care for head and neck cancer.


  • Open Access

    Diffuse large cell type B breast lymphoma: case report

    by Lamyae Nouiakh, Karima Oualla, Imane Ouafki, Soumia Berrad, Hayat Erraichi, Younes Dkhissi, Lamiae Amaadour, Zineb Benbrahim, Samia Arifi, Meryem Boubou, et al.

  • Open Access

    Immunotherapeutic Approaches in Triple-Negative Breast Cancer: State of the Art and Future Perspectives

    by Karima Oualla, Loay Kassem, Lamiae Nouiakh, Lamiae Amaadour, Zineb Benbrahim, Samia Arifi, Nawfel Mellas

    Triple-negative breast cancer (TNBC) is characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). It accounts for 15%–20% of all breast cancers and is associated with an aggressive evolution and poor outcomes with the majority of recurrences and deaths occurring in the first 5 years. Chemotherapy remains the mainstay of treatment in the absence of effective targets, but the good understanding of immune tumor microenvironment, the identification of immune-related targets, and the role of tumor-infiltrating lymphocytes (TILs) in TNBC has allowed to develop promising immunotherapeutic strategies for this unique subset of breast cancer. Recently, immunotherapy is being extensively explored in TNBC and clinical trials have shown promising results. In this article, we tried to explain the rationale and mechanisms of targeting the immune system in TNBC, to report the results from recent clinical trials that put immunotherapy as a new standard of care in TNBC in addition to ongoing trials and future directions in the next decade.


  • Open Access

    How Is Morocco Reacting to COVID-19 Crisis in Anticancer Centers?

    by Karima Oualla, Lamiae Nouiakh, Nisrine Acharfi, Lamiae Amaadour, Zineb Benbrahim, Samia Arifi, Nawfel Mellas

    The world is facing the pandemic linked to COVID-19 virus infection that has rapidly spread worldwide, and severe complications have been reported to occur in around a third of patients. To date, there is no approved vaccine or specific therapy against COVID-19, but many trials are ongoing with some of them showing promising results. It has been shown recently that patients with cancer are at high risk of infection and they are more susceptible to develop severe events such as the necessity of invasive ventilation and death. Therefore, this crisis presents a real challenge for health systems especially in low- and middle-income countries where the health systems are already fragile such as African countries. In this article, we describe the epidemiological situation of the infection in Morocco and the different challenges in cancer centers in the era of COVID-19, in addition to various strategies that have been implemented to prevent and control the infection spread in oncological units in order to ensure the continuation of adequate cancer care.